Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660529 · ClinicalTrials.gov registry record · Early Phase 1
Multi-peptide Vaccine With Basilixumab for Breast Cancer
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT01660529 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants.
The verdict
NCT01660529, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Eligible patients will receive subcutaneous vaccinations of the hTERT/survivin/CMV multipeptide vaccine and GM-CSF over a 24 month period. All patients will receive basiliximab 20 mg 1 day prior to the start of vaccinations. Prevnar vaccine will be administered at the time of Vaccines 1,3, and 5. Patients who remain clinically stable after the fourth vaccine, may continue to receive vaccinations every 4 weeks for up to 2 years.
Interventions
- BIOLOGICAL hTERT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-11-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01660529
The ClinicalTrials.gov registry entry for NCT01660529 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hTERT is the first listed.
NCT01660529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01660529 about?
NCT01660529 is a clinical study titled "Multi-peptide Vaccine With Basilixumab for Breast Cancer". Eligible patients will receive subcutaneous vaccinations of the hTERT/survivin/CMV multipeptide vaccine and GM-CSF over a 24 month period. All patients will receive basiliximab 20 mg 1 day prior to the start of vaccinations. Prevnar vaccine will be administered at the time of Vaccines 1,3, and 5. Pa...
What is the current status of trial NCT01660529?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2012-06. Estimated completion is 2015-11-20.
What interventions are being tested in trial NCT01660529?
The interventions under investigation include: hTERT (BIOLOGICAL).
Who is sponsoring clinical trial NCT01660529?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.